Onco‑Innovations Limited Advances Metabolism Studies for Lead Nanoparticle‑Formulated PNKP Inhibitor ONC010

Onco‑Innovations Limited, a Canadian biotech company listed on the NEO Exchange and traded under the symbols ONCO (CBOE CA) and ONNVF (OTCQB), announced on 26 June 2026 that it has begun a three‑species hepatocyte and liver microsome metabolism program for its lead product candidate, ONC010. The compound is a nanoparticle‑formulated inhibitor of the DNA repair enzyme polynucleotide kinase‑phosphatase (PNKP) and is intended for the treatment of solid tumours.

Program Scope and Objectives

The studies, carried out by Nucro‑Technics, a Canadian provider of IND‑enabling preclinical services, will assess metabolic stability and clearance of ONC010 in human, rat, and dog systems. Both hepatocyte and microsome platforms are being employed to capture complementary aspects of liver metabolism: whole‑cell hepatocytes provide data on intrinsic clearance and overall metabolic degradation, while microsomes focus on enzyme‑mediated reactions. Dr. Islam Mohamed, Chief Medical Officer, stated that the resulting data will support:

  • Pharmacokinetic modelling and dose‑selection decisions
  • Toxicology studies and safety assessments
  • Regulatory submissions for IND application

These studies are part of an integrated IND‑enabling strategy that also includes ADME, bioanalytical, manufacturing, formulation, and clinical translation activities.

Supporting Developments

Earlier on 24 June 2026, Onco‑Innovations announced a service agreement with Nanosoft Polymers to accelerate the development of polymer formulations and drug delivery systems for ONC010, further underpinning the company’s commitment to optimize the nanoparticle platform.

The company’s placement in a recent editorial by BioMedWire (published 25 June 2026) highlighted its position within a network of over 75 brands focused on financial communications for private and public companies, underscoring the growing interest in ONC010’s novel mechanism of action.

An audio press release by NetworkNewsAudio (26 June 2026) also discussed ONC010’s development, positioning it within the broader landscape of next‑generation DNA repair therapies in oncology.

Company Profile

Onco‑Innovations Limited operates in the health‑care sector with a market cap of 51 147 164 CAD. The company’s mandate is to advance oncology therapeutics worldwide, leveraging innovative nanotechnology to improve drug delivery and efficacy.

Key Takeaway: Onco‑Innovations Limited has initiated comprehensive three‑species metabolism studies for ONC010, a nanoparticle‑based PNKP inhibitor, as part of its IND‑enabling pipeline. The data generated will inform pharmacokinetic modelling, dose selection, and regulatory strategy, while concurrent partnership with Nanosoft Polymers and media coverage reinforce the company’s momentum in developing next‑generation oncology agents.